StockData

Cartesian Therapeutics, Inc. (RNAC) income statement

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.30+0.18 (+2.94%)

Close on Nov 18, 2026Market cap $190.61MP/E –Yield –

Cartesian Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-10518.6%
Net margin
-10283.8%
Return on equity, FY2025
195.9%

Financial strength

Current ratio
7.48
Debt to equity
-0.42
Debt to assets
16.6%
Cash to current liabilities
718.3%

Valuation

P/E ratio
–
Price to sales
129.05
Price to book
–
Dividend yield
–

See a number that looks wrong?